Verzenio(abemaciclib)
Verzenio 50 MG Oral Tablet
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
Most viewed Verzenio resources
Coverage Restrictions
Find Restrictions and Step Therapies for Verzenio
drug label
Verzenio Prescribing Information
samples
Request Verzenio Samples
pharmacy
Verzenio Preferred Pharmacy
Financial Assistance
Financial Assistance Programs
Verzenio retails for $290 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Verzenio for significantly less. Review the program information below to determine what program can offer your patient the most benefits.Patient Assistance Program28 days supply for as low as $0
Available for
commercial
Program Details
- Program Expires 12/31/2024
- $25000 Annual Cap
Forms
Foundation ProgramFirst dose for $0
Available for
medicare
uninsured
Eligibility requirements
- Uninsured
- Medicare Part D
- Household annual adjusted gross income <= 500% FPL.
Forms
patient education
Verzenio Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Verzenio FAQs
What is VERZENIO?VERZENIO is a medication used to treat certain types of breast cancer.
Can VERZENIO cause harm to a fetus if taken during pregnancy?Yes, based on animal studies and its mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman. There are no available human data informing the drug-associated risk. Pregnant women should be advised of the potential risk to a fetus.
What are the potential risks to a fetus if a pregnant woman takes VERZENIO?In animal reproduction studies, administration of abemaciclib (the active ingredient in VERZENIO) during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose. Doses ≥4 mg/kg/day in pregnant rats caused decreased fetal body weights and increased incidence of cardiovascular and skeletal malformations and variations.
What is the background risk of major birth defects and miscarriage for the indicated population?The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.
Can VERZENIO be taken during lactation?No, there are no data on the presence of abemaciclib (the active ingredient in VERZENIO) in human milk, or its effects on the breastfed child or on milk production. Lactating women should be advised not to breastfeed during VERZENIO treatment and for 3 weeks after the last dose.
Can VERZENIO affect fertility in males of reproductive potential?Yes, based on findings in animals, VERZENIO may impair fertility in males of reproductive potential.
Should females of reproductive potential use contraception during VERZENIO treatment?Yes, females of reproductive potential should use effective contraception during VERZENIO treatment and for 3 weeks after the last dose.
Is VERZENIO safe and effective for use in pediatric patients?The safety and effectiveness of VERZENIO have not been established in pediatric patients.
Is VERZENIO safe and effective for use in geriatric patients?No overall differences in safety or effectiveness of VERZENIO were observed between older patients (65 years of age or older) and younger patients. However, the most common adverse reactions in older patients were neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and ALT increased.
Is dosage adjustment necessary for patients with renal impairment?No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr ≥30-89 mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr <30 mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown.
Is dosage adjustment necessary for patients with hepatic impairment?No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B). Reduce the dosing frequency when administering VERZENIO to patients with severe hepatic impairment (Child-Pugh C).
FAQ Data Source